Barclays’s Evogene EVGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-5
| Closed | – | – | 4273 |
|
|
2021
Q3 | $0 | Sell |
5
-7
| -58% | -$204 | ﹤0.01% | 4812 |
|
|
2021
Q2 | $0 | Buy |
12
+7
| +140% | +$274 | ﹤0.01% | 4923 |
|
|
2021
Q1 | $0 | Buy |
+5
| New | +$309 | ﹤0.01% | 4834 |
|
|
2020
Q2 | – | Sell |
-70
| Closed | -$1K | – | 5741 |
|
|
2020
Q1 | $1K | Hold |
70
| – | – | ﹤0.01% | 6071 |
|
|
2019
Q4 | $1K | Hold |
70
| – | – | ﹤0.01% | 6272 |
|
|
2019
Q3 | $1K | Sell |
70
-29
| -29% | -$456 | ﹤0.01% | 6584 |
|
|
2019
Q2 | $2K | Hold |
99
| – | – | ﹤0.01% | 6798 |
|
|
2019
Q1 | $2K | Buy |
+99
| New | +$2.09K | ﹤0.01% | 6852 |
|
|
2018
Q4 | – | Sell |
-4,933
| Closed | -$153K | – | 7039 |
|
|
2018
Q3 | $153K | Hold |
4,933
| – | – | ﹤0.01% | 5207 |
|
|
2018
Q2 | $141K | Hold |
4,933
| – | – | ﹤0.01% | 5017 |
|
|
2018
Q1 | $157K | Hold |
4,933
| – | – | ﹤0.01% | 5038 |
|
|
2017
Q4 | $151K | Hold |
4,933
| – | – | ﹤0.01% | 4920 |
|
|
2017
Q3 | $219K | Hold |
4,933
| – | – | ﹤0.01% | 4350 |
|
|
2017
Q2 | $250K | Hold |
4,933
| – | – | ﹤0.01% | 4175 |
|
|
2017
Q1 | $264K | Hold |
4,933
| – | – | ﹤0.01% | 4046 |
|
|
2016
Q4 | $252K | Hold |
4,933
| – | – | ﹤0.01% | 4015 |
|
|
2016
Q3 | $315K | Hold |
4,933
| – | – | ﹤0.01% | 3608 |
|
|
2016
Q2 | $308K | Hold |
4,933
| – | – | ﹤0.01% | 3605 |
|
|
2016
Q1 | $296K | Sell |
4,933
-781
| -14% | -$53.6K | ﹤0.01% | 3562 |
|
|
2015
Q4 | $457K | Buy |
5,714
+246
| +4% | +$18.3K | ﹤0.01% | 3286 |
|
|
2015
Q3 | $438K | Buy |
5,468
+265
| +5% | +$23.1K | ﹤0.01% | 3466 |
|
|
2015
Q2 | $417K | Buy |
5,203
+270
| +5% | +$26.1K | ﹤0.01% | 3616 |
|
|
2015
Q1 | $395K | Hold |
4,933
| – | – | ﹤0.01% | 3816 |
|
|
2014
Q4 | $444K | Hold |
4,933
| – | – | ﹤0.01% | 3980 |
|
|
2014
Q3 | $641K | Hold |
4,933
| – | – | ﹤0.01% | 3740 |
|
|
2014
Q2 | $789K | Sell |
4,933
-143
| -3% | -$24.6K | ﹤0.01% | 3551 |
|
|
2014
Q1 | $964K | Buy |
5,076
+143
| +3% | +$27.1K | ﹤0.01% | 3272 |
|
|
2013
Q4 | $937K | Buy |
+4,933
| New | +$911K | ﹤0.01% | 3468 |
|
Other funds holding EVGN
AIM
SCM
SM
EVC
Barclays's EVGN Position: Q4 2021 in Review
Barclays sold out of Evogene (EVGN) in Q4 2021, closing a stake of 5 shares.
Barclays first reported a position in EVGN in Q4 2013 and held it in 28 quarters. The position peaked at $964K in Q1 2014. 42 funds tracked by Wall St. Rank hold EVGN as of Q4 2021.
- Barclays reported no remaining Evogene position as of Q4 2021 after selling out during the quarter.
- Barclays sold 5 Evogene shares in Q4 2021.
- Barclays first reported a position in Evogene in Q4 2013 and held it in 28 quarters.
- Barclays's Evogene position peaked at $964K in Q1 2014.
- 42 funds tracked by Wall St. Rank held Evogene as of Q4 2021.
Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.